Patents by Inventor Paul Parren

Paul Parren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
    Publication number: 20240132620
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: August 17, 2023
    Publication date: April 25, 2024
    Inventors: Michel DE WEERS, Yvo GRAUS, Judith OPRINS, Paul PARREN, Jan VAN DE WINKEL, Martine VAN VUGT
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240117064
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: April 11, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11939388
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: March 26, 2024
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • ANTIBODIES BINDING AXL
    Publication number: 20240091352
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: February 28, 2023
    Publication date: March 21, 2024
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • MONOCLONAL ANTIBODIES AGAINST C-MET
    Publication number: 20240084036
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: October 25, 2022
    Publication date: March 14, 2024
    Inventors: Joost J. NEIJSSEN, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240076397
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 7, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Heterodimeric antibody Fc-containing proteins and methods for production thereof
    Patent number: 11866514
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: January 9, 2024
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20230416403
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 6, 2022
    Publication date: December 28, 2023
    Inventors: Sandra VERPLOEGEN, David P. E. SATIJN, Rene M. A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230399414
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: December 14, 2023
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D.CHAMULEAU, Tuna MUTIS
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20230374131
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: February 14, 2023
    Publication date: November 23, 2023
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)
    Patent number: 11814411
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: November 14, 2023
    Assignees: BIONTECH SE, GENMAB A/S
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
    Patent number: 11795214
    Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 24, 2023
    Assignee: GENMAB A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald Van Den Bremer
  • INERT FORMAT
    Publication number: 20230322947
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Application
    Filed: September 22, 2022
    Publication date: October 12, 2023
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Edward Norbert VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20230321261
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: September 30, 2022
    Publication date: October 12, 2023
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20230312693
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 5, 2023
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO, Jeffrey B STAVENHAGEN
  • BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER
    Publication number: 20230257479
    Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Type: Application
    Filed: September 11, 2020
    Publication date: August 17, 2023
    Inventors: David SATIJN, Esther C.W. BREIJ, Bart E.C.G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN, Reshma Abdulla RANGWALA, Sri GHATTA, Ruud BRAKENHOFF, Rieneke VAN DE VEN
  • PRODUCTION OF HETERODIMERIC PROTEINS
    Publication number: 20230227495
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: September 7, 2022
    Publication date: July 20, 2023
    Inventors: Michael GRAMER, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Amout F. Gerritsen
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20230159643
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Soren Christensen, Jan Egebjerg, Amout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • POLYPEPTIDE VARIANTS AND USES THEREOF
    Publication number: 20230107363
    Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.
    Type: Application
    Filed: May 16, 2022
    Publication date: April 6, 2023
    Inventors: Rob DE JONG, Frank Beurskens, Marije Overdijk, Kristin STRUMANE, Janine Schuurman, Paul Parren
  • Humanized or chimeric CD3 antibodies
    Patent number: 11613575
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: March 28, 2023
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker